Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HDM1002 in Overweight and Obese Adults
NCT06500299Phase 2Not yet recruiting
- Sponsor
- Huadong Medicine
- Start
- Jul 2024
- Primary completion
- Oct 2024
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of conveglipron in obesity and Overweight (4 arms), sponsored by Huadong Medicine. Primary endpoint: Percentage Change From Baseline in Body Weight at 12 weeks. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
conveglipron
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT06500299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06500299.